公开(公告)号：WO2022061461A1

公开(公告)日：2022-03-31

申请号：PCT/CA2021/051327

申请日：2021-09-23

Applicant: TETRA BIO-PHARMA INC.

Inventor： KAUR, Harpreet ,  LIU, Xuejun ,  NEPAL, Prabin ,  PARAMANANTHAM, Subakar ,  GARG, Monika ,  LI, Zemin ,  TJENG, Andy ,  RODRIGUEZ, Moises ,  JONG, Laura ,  MIRZAHOSSEIN, Azam ,  YIFRACH-STAV, Ofer ,  BASSETT, Erin ,  RINGUETTE, Randy ,  CAMPBELL, Charles ,  KELLY, Melanie

IPC: C07C229/12 ,  C07C41/06 ,  C07C41/34 ,  C07C43/196

Abstract: Disclosed herein are methods, processes and compositions for preparing a compound of formula 8: (8), and formula 18: (18). The methods and processes comprise performing a first allylic oxidation, a protection reaction, a second allylic oxidation, a reduction reaction, performing an acid-catalyzed coupling reaction, a methylation reaction and a deprotection reaction. Disclosed herein are methods, processes and compositions for enantioselectively preparing compounds of formulae 8 and 18. Also disclosed herein are compositions comprising compounds of formulae 8, 18 and/or intermediates and/or starting material thereof.

公开(公告)号：WO2018205038A1

公开(公告)日：2018-11-15

申请号：PCT/CA2018/050572

申请日：2018-05-14

Applicant: TETRA BIO-PHARMA INC.

Inventor： RINGUETTE, Randy ,  CAMPBELL, Charles

IPC: A61K31/352 ,  A61K31/01 ,  A61K31/015 ,  A61K31/045 ,  A61K31/05 ,  A61K31/15 ,  A61K31/164 ,  A61K31/165 ,  A61K31/198 ,  A61K31/22 ,  A61K31/5383 ,  A61K31/57 ,  A61K36/185 ,  C07C11/21 ,  C07C13/21 ,  C07C13/271 ,  C07C13/42 ,  C07C233/01 ,  C07C233/17 ,  C07C233/18 ,  C07C39/19 ,  C07C39/23 ,  C07C69/67 ,  C07D311/60 ,  C07D311/80 ,  C07D498/06

CPC classification number: A61K36/185 ,  A61K31/01 ,  A61K31/015 ,  A61K31/045 ,  A61K31/05 ,  A61K31/15 ,  A61K31/164 ,  A61K31/165 ,  A61K31/198 ,  A61K31/22 ,  A61K31/352 ,  A61K31/5383 ,  A61K45/06 ,  A61K2300/00

Abstract: Pharmaceutical compositions comprising a mixture of cannabinoids and terpenes and use thereof in the treatment of select disorders mediated by the Hedgehog (HH) signaling pathway are disclosed. In preferred embodiments, the components of the composition synergistically inhibit HH signaling such that they serve to treat cancer and ocular disorders associated with aberrant neovascularization (such as age-related macular degeneration). The cannabinoids to be used include phytocannabinoids (such as tetrahydrocannabinol and cannabidiol), endogenous cannabinoids (such as the N-acylethanolamides), or synthetic cannabinoids. Preferred terpenes for use include those that naturally occur in Cannabis plants (such as pinene, limonene, linalool, and phytol).

公开(公告)号：WO2022133612A1

公开(公告)日：2022-06-30

申请号：PCT/CA2021/051882

申请日：2021-12-23

Applicant: TETRA BIO-PHARMA INC.

Inventor： KAUR, Harpreet ,  FAROOQ, Hashim ,  THIRUNAVUKARASU, Subhagini ,  GEORGEWILL, Dawaye ,  WANG, Jixing ,  XU, Di ,  SHARIF, Omar ,  KELLY, Melanie ,  WOOD, Graham ,  CAMPBELL, Charles ,  BASSETT, Erin ,  HUNG, Orlando ,  LEHMANN, Christian

IPC: A61K31/09 ,  A61K9/107 ,  A61K47/14 ,  A61K47/24 ,  A61K47/44 ,  A61P29/00 ,  B01F23/50 ,  B01F33/71 ,  C07C43/23

Abstract: Pharmaceutical compositions for parenteral delivery of cannabinoids are disclosed herein. The pharmaceutical compositions comprise onternabez, a first solvent, and a first emulsifier. Uses thereof and methods of producing the compositions are also disclosed.

公开(公告)号：WO2020124220A1

公开(公告)日：2020-06-25

申请号：PCT/CA2019/051833

申请日：2019-12-17

Applicant: TETRA BIO-PHARMA INC.

Inventor： CHAMBERLAND, Guy ,  CAMPBELL, Charles ,  RINGUETTE, Randy ,  BASSETT, Jennifer Dorothy ,  YIFRACH-STAV, Ofer ,  RACKOV, Andrien ,  FORD, Peter

IPC: A61K31/352 ,  A61K31/05 ,  A61K31/192 ,  A61K36/185 ,  A61K9/72 ,  C07C39/19 ,  C07C39/23 ,  C07C65/19 ,  C07D311/74 ,  C07D311/80

Abstract: Provided are pharmaceutical compositions comprising cannabis such that when combusted produces cannabidiolic acid (CBDA) for inhalation. Also provided are pharmaceutical composition for inhalation by a subject comprising tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabidiolic acid (CBDA), and cannabigerol (CBG). Also provided are methods of enhancing cannabidiolic acid (CBDA) in a pharmaceutical composition for inhalation. Methods of use of embodiments of the pharmaceutical composition and kits comprising embodiments of the pharmaceutical composition are provided herein. Unit dosage form medicaments and compositions for vaporization by a subject comprising cannabinoids are also disclosed herein.